|
| | 103RD GENERAL ASSEMBLY
State of Illinois
2023 and 2024 SB3640 Introduced 2/9/2024, by Sen. Patrick J. Joyce SYNOPSIS AS INTRODUCED: | | 720 ILCS 570/208 | from Ch. 56 1/2, par. 1208 | 720 ILCS 570/309.1 new | | 720 ILCS 570/401 | from Ch. 56 1/2, par. 1401 |
| Amends the Illinois Controlled Substances Act. Schedules Xylazine as a Schedule III controlled substance. Provides for penalties for the knowing manufacture or delivery, or possession with intent to manufacture or deliver xylazine. Provides that, notwithstanding the scheduling of Xylazine as a Schedule III controlled substance, the prohibition on delivery or possession with intent to deliver Xylazine does not apply to licensed veterinarians who lawfully prescribe, dispense, administer, acquire, or use any controlled substance, including Xylazine, while acting in the course of their professional practice, in good faith, and in accordance with generally accepted medical standards. |
| |
| | A BILL FOR |
|
|
| | SB3640 | | LRB103 37597 RLC 69548 b |
|
|
1 | | AN ACT concerning criminal law. |
2 | | Be it enacted by the People of the State of Illinois, |
3 | | represented in the General Assembly: |
4 | | Section 5. The Illinois Controlled Substances Act is |
5 | | amended by changing Sections 208 and 401 and by adding Section |
6 | | 309.1 as follows: |
7 | | (720 ILCS 570/208) (from Ch. 56 1/2, par. 1208) |
8 | | Sec. 208. (a) The controlled substances listed in this |
9 | | Section are included in Schedule III. |
10 | | (b) Unless specifically excepted or unless listed in |
11 | | another schedule, any material, compound, mixture, or |
12 | | preparation which contains any quantity of the following |
13 | | substances having a stimulant effect on the central nervous |
14 | | system, including its salts, isomers (whether optical |
15 | | position, or geometric), and salts of such isomers whenever |
16 | | the existence of such salts, isomers, and salts of isomers is |
17 | | possible within the specific chemical designation; |
18 | | (1) Those compounds, mixtures, or preparations in |
19 | | dosage unit form containing any stimulant substances |
20 | | listed in Schedule II which compounds, mixtures, or |
21 | | preparations were listed on August 25, 1971, as excepted |
22 | | compounds under Title 21, Code of Federal Regulations, |
23 | | Section 308.32, and any other drug of the quantitative |
|
| | SB3640 | - 2 - | LRB103 37597 RLC 69548 b |
|
|
1 | | composition shown in that list for those drugs or which is |
2 | | the same except that it contains a lesser quantity of |
3 | | controlled substances; |
4 | | (2) Benzphetamine; |
5 | | (3) Chlorphentermine; |
6 | | (4) Clortermine; |
7 | | (5) Phendimetrazine. |
8 | | (c) Unless specifically excepted or unless listed in |
9 | | another schedule, any material, compound, mixture, or |
10 | | preparation which contains any quantity of the following |
11 | | substances having a potential for abuse associated with a |
12 | | depressant effect on the central nervous system: |
13 | | (1) Any compound, mixture, or preparation containing |
14 | | amobarbital, secobarbital, pentobarbital or any salt |
15 | | thereof and one or more other active medicinal ingredients |
16 | | which are not listed in any schedule; |
17 | | (2) Any suppository dosage form containing |
18 | | amobarbital, secobarbital, pentobarbital or any salt of |
19 | | any of these drugs and approved by the Federal Food and |
20 | | Drug Administration for marketing only as a suppository; |
21 | | (3) Any substance which contains any quantity of a |
22 | | derivative of barbituric acid, or any salt thereof: |
23 | | (3.1) Aprobarbital; |
24 | | (3.2) Butabarbital (secbutabarbital); |
25 | | (3.3) Butalbital; |
26 | | (3.4) Butobarbital (butethal); |
|
| | SB3640 | - 3 - | LRB103 37597 RLC 69548 b |
|
|
1 | | (4) Chlorhexadol; |
2 | | (5) Methyprylon; |
3 | | (6) Sulfondiethylmethane; |
4 | | (7) Sulfonethylmethane; |
5 | | (8) Sulfonmethane; |
6 | | (9) Lysergic acid; |
7 | | (10) Lysergic acid amide; |
8 | | (10.1) Tiletamine or zolazepam or both, or any salt of |
9 | | either of them. |
10 | | Some trade or other names for a tiletamine-zolazepam
|
11 | | combination product: Telazol.
|
12 | | Some trade or other names for Tiletamine:
|
13 | | 2-(ethylamino)-2-(2-thienyl)-cyclohexanone.
|
14 | | Some trade or other names for zolazepam:
|
15 | | 4-(2-fluorophenyl)-6,8-dihydro-1,3,8-trimethylpyrazolo-
|
16 | | [3,4-e], [1,4]-diazepin-7(1H)-one, and flupyrazapon. |
17 | | (11) Any material, compound, mixture or preparation |
18 | | containing not more than 12.5 milligrams of pentazocine or |
19 | | any of its salts, per 325 milligrams of aspirin; |
20 | | (12) Any material, compound, mixture or preparation |
21 | | containing not more than 12.5 milligrams of pentazocine or |
22 | | any of its salts, per 325 milligrams of acetaminophen; |
23 | | (13) Any material, compound, mixture or preparation |
24 | | containing not more than 50 milligrams of pentazocine or |
25 | | any of its salts plus naloxone HCl USP 0.5 milligrams, per |
26 | | dosage unit; |
|
| | SB3640 | - 4 - | LRB103 37597 RLC 69548 b |
|
|
1 | | (14) Ketamine; |
2 | | (15) Thiopental ; . |
3 | | (16) Xylazine. |
4 | | (d) Nalorphine. |
5 | | (d.5) Buprenorphine. |
6 | | (e) Unless specifically excepted or unless listed in |
7 | | another schedule, any material, compound, mixture, or |
8 | | preparation containing limited quantities of any of the |
9 | | following narcotic drugs, or their salts calculated as the |
10 | | free anhydrous base or alkaloid, as set forth below: |
11 | | (1) not more than 1.8 grams of codeine per 100 |
12 | | milliliters or not more than 90 milligrams per dosage |
13 | | unit, with an equal or greater quantity of an isoquinoline |
14 | | alkaloid of opium; |
15 | | (2) not more than 1.8 grams of codeine per 100 |
16 | | milliliters or not more than 90 milligrams per dosage |
17 | | unit, with one or more active non-narcotic ingredients in |
18 | | recognized therapeutic amounts; |
19 | | (3) (blank); |
20 | | (4) (blank); |
21 | | (5) not more than 1.8 grams of dihydrocodeine per 100 |
22 | | milliliters or not more than 90 milligrams per dosage |
23 | | unit, with one or more active, non-narcotic ingredients in |
24 | | recognized therapeutic amounts; |
25 | | (6) not more than 300 milligrams of ethylmorphine per |
26 | | 100 milliliters or not more than 15 milligrams per dosage |
|
| | SB3640 | - 5 - | LRB103 37597 RLC 69548 b |
|
|
1 | | unit, with one or more active, non-narcotic ingredients in |
2 | | recognized therapeutic amounts; |
3 | | (7) not more than 500 milligrams of opium per 100 |
4 | | milliliters or per 100 grams, or not more than 25 |
5 | | milligrams per dosage unit, with one or more active, |
6 | | non-narcotic ingredients in recognized therapeutic |
7 | | amounts; |
8 | | (8) not more than 50 milligrams of morphine per 100 |
9 | | milliliters or per 100 grams with one or more active, |
10 | | non-narcotic ingredients in recognized therapeutic |
11 | | amounts. |
12 | | (f) Anabolic steroids, except the following anabolic |
13 | | steroids that are exempt: |
14 | | (1) Androgyn L.A.; |
15 | | (2) Andro-Estro 90-4; |
16 | | (3) depANDROGYN; |
17 | | (4) DEPO-T.E.; |
18 | | (5) depTESTROGEN; |
19 | | (6) Duomone; |
20 | | (7) DURATESTRIN; |
21 | | (8) DUO-SPAN II; |
22 | | (9) Estratest; |
23 | | (10) Estratest H.S.; |
24 | | (11) PAN ESTRA TEST; |
25 | | (12) Premarin with Methyltestosterone; |
26 | | (13) TEST-ESTRO Cypionates; |
|
| | SB3640 | - 6 - | LRB103 37597 RLC 69548 b |
|
|
1 | | (14) Testosterone Cyp 50 Estradiol Cyp 2; |
2 | | (15) Testosterone Cypionate-Estradiol Cypionate |
3 | | injection; and |
4 | | (16) Testosterone Enanthate-Estradiol Valerate |
5 | | injection. |
6 | | (g) Hallucinogenic substances. |
7 | | (1) Dronabinol (synthetic) in sesame oil and |
8 | | encapsulated in a soft gelatin capsule in a U.S. Food and |
9 | | Drug Administration approved product. Some other names for |
10 | | dronabinol: (6aR-trans)-6a,7,8,10a-tetrahydro- |
11 | | 6,6,9-trimethyl-3-pentyl-6H-dibenzo (b,d) pyran-1-ol) or |
12 | | (-)-delta-9-(trans)-tetrahydrocannabinol. |
13 | | (2) (Reserved). |
14 | | (h) The Department may except by rule any compound, |
15 | | mixture, or preparation containing any stimulant or depressant |
16 | | substance listed in subsection (b) from the application of all |
17 | | or any part of this Act if the compound, mixture, or |
18 | | preparation contains one or more active medicinal ingredients |
19 | | not having a stimulant or depressant effect on the central |
20 | | nervous system, and if the admixtures are included therein in |
21 | | combinations, quantity, proportion, or concentration that |
22 | | vitiate the potential for abuse of the substances which have a |
23 | | stimulant or depressant effect on the central nervous system. |
24 | | (Source: P.A. 100-368, eff. 1-1-18 .) |
25 | | (720 ILCS 570/309.1 new) |
|
| | SB3640 | - 7 - | LRB103 37597 RLC 69548 b |
|
|
1 | | Sec. 309.1. Veterinarian; Xylazine. Notwithstanding the |
2 | | scheduling of Xylazine as a Schedule III controlled substance, |
3 | | the prohibition on delivery or possession with intent to |
4 | | deliver Xylazine does not apply to licensed veterinarians who |
5 | | lawfully prescribe, dispense, administer, acquire, or use any |
6 | | controlled substance, including Xylazine, while acting in the |
7 | | course of their professional practice, in good faith, and in |
8 | | accordance with generally accepted medical standards. |
9 | | (720 ILCS 570/401) (from Ch. 56 1/2, par. 1401) |
10 | | Sec. 401. Manufacture or delivery, or possession with |
11 | | intent to manufacture or deliver, a controlled substance, a |
12 | | counterfeit substance, or controlled substance analog. Except |
13 | | as authorized by this Act, it is unlawful for any person |
14 | | knowingly to manufacture or deliver, or possess with intent to |
15 | | manufacture or deliver, a controlled substance other than |
16 | | methamphetamine and other than bath salts as defined in the |
17 | | Bath Salts Prohibition Act sold or offered for sale in a retail |
18 | | mercantile establishment as defined in Section 16-0.1 of the |
19 | | Criminal Code of 2012, a counterfeit substance, or a |
20 | | controlled substance analog. A violation of this Act with |
21 | | respect to each of the controlled substances listed herein |
22 | | constitutes a single and separate violation of this Act. For |
23 | | purposes of this Section, "controlled substance analog" or |
24 | | "analog" means a substance, other than a controlled substance, |
25 | | which is not approved by the United States Food and Drug |
|
| | SB3640 | - 8 - | LRB103 37597 RLC 69548 b |
|
|
1 | | Administration or, if approved, is not dispensed or possessed |
2 | | in accordance with State or federal law, and that has a |
3 | | chemical structure substantially similar to that of a |
4 | | controlled substance in Schedule I or II, or that was |
5 | | specifically designed to produce an effect substantially |
6 | | similar to that of a controlled substance in Schedule I or II. |
7 | | Examples of chemical classes in which controlled substance |
8 | | analogs are found include, but are not limited to, the |
9 | | following: phenethylamines, N-substituted piperidines, |
10 | | morphinans, ecgonines, quinazolinones, substituted indoles, |
11 | | and arylcycloalkylamines. For purposes of this Act, a |
12 | | controlled substance analog shall be treated in the same |
13 | | manner as the controlled substance to which it is |
14 | | substantially similar. |
15 | | (a) Any person who violates this Section with respect to |
16 | | the following amounts of controlled or counterfeit substances |
17 | | or controlled substance analogs, notwithstanding any of the |
18 | | provisions of subsections (c), (d), (e), (f), (g) or (h) to the |
19 | | contrary, is guilty of a Class X felony and shall be sentenced |
20 | | to a term of imprisonment as provided in this subsection (a) |
21 | | and fined as provided in subsection (b): |
22 | | (1)(A) not less than 6 years and not more than 30 years |
23 | | with respect to 15 grams or more but less than 100 grams of |
24 | | a substance containing heroin, or an analog thereof; |
25 | | (B) not less than 9 years and not more than 40 years |
26 | | with respect to 100 grams or more but less than 400 grams |
|
| | SB3640 | - 9 - | LRB103 37597 RLC 69548 b |
|
|
1 | | of a substance containing heroin, or an analog thereof; |
2 | | (C) not less than 12 years and not more than 50 years |
3 | | with respect to 400 grams or more but less than 900 grams |
4 | | of a substance containing heroin, or an analog thereof; |
5 | | (D) not less than 15 years and not more than 60 years |
6 | | with respect to 900 grams or more of any substance |
7 | | containing heroin, or an analog thereof; |
8 | | (1.5)(A) not less than 6 years and not more than 30 |
9 | | years with respect to 15 grams or more but less than 100 |
10 | | grams of a substance containing fentanyl or xylazine , or |
11 | | an analog thereof; |
12 | | (B) not less than 9 years and not more than 40 years |
13 | | with respect to 100 grams or more but less than 400 grams |
14 | | of a substance containing fentanyl or xylazine , or an |
15 | | analog thereof; |
16 | | (C) not less than 12 years and not more than 50 years |
17 | | with respect to 400 grams or more but less than 900 grams |
18 | | of a substance containing fentanyl or xylazine , or an |
19 | | analog thereof; |
20 | | (D) not less than 15 years and not more than 60 years |
21 | | with respect to 900 grams or more of a substance |
22 | | containing fentanyl or xylazine , or an analog thereof; |
23 | | (2)(A) not less than 6 years and not more than 30 years |
24 | | with respect to 15 grams or more but less than 100 grams of |
25 | | a substance containing cocaine, or an analog thereof; |
26 | | (B) not less than 9 years and not more than 40 years |
|
| | SB3640 | - 10 - | LRB103 37597 RLC 69548 b |
|
|
1 | | with respect to 100 grams or more but less than 400 grams |
2 | | of a substance containing cocaine, or an analog thereof; |
3 | | (C) not less than 12 years and not more than 50 years |
4 | | with respect to 400 grams or more but less than 900 grams |
5 | | of a substance containing cocaine, or an analog thereof; |
6 | | (D) not less than 15 years and not more than 60 years |
7 | | with respect to 900 grams or more of any substance |
8 | | containing cocaine, or an analog thereof; |
9 | | (3)(A) not less than 6 years and not more than 30 years |
10 | | with respect to 15 grams or more but less than 100 grams of |
11 | | a substance containing morphine, or an analog thereof; |
12 | | (B) not less than 9 years and not more than 40 years |
13 | | with respect to 100 grams or more but less than 400 grams |
14 | | of a substance containing morphine, or an analog thereof; |
15 | | (C) not less than 12 years and not more than 50 years |
16 | | with respect to 400 grams or more but less than 900 grams |
17 | | of a substance containing morphine, or an analog thereof; |
18 | | (D) not less than 15 years and not more than 60 years |
19 | | with respect to 900 grams or more of a substance |
20 | | containing morphine, or an analog thereof; |
21 | | (4) 200 grams or more of any substance containing |
22 | | peyote, or an analog thereof; |
23 | | (5) 200 grams or more of any substance containing a |
24 | | derivative of barbituric acid or any of the salts of a |
25 | | derivative of barbituric acid, or an analog thereof; |
26 | | (6) 200 grams or more of any substance containing |
|
| | SB3640 | - 11 - | LRB103 37597 RLC 69548 b |
|
|
1 | | amphetamine or any salt of an optical isomer of |
2 | | amphetamine, or an analog thereof; |
3 | | (6.5) (blank); |
4 | | (6.6) (blank); |
5 | | (7)(A) not less than 6 years and not more than 30 years |
6 | | with respect to: (i) 15 grams or more but less than 100 |
7 | | grams of a substance containing lysergic acid diethylamide |
8 | | (LSD), or an analog thereof, or (ii) 15 or more objects or |
9 | | 15 or more segregated parts of an object or objects but |
10 | | less than 200 objects or 200 segregated parts of an object |
11 | | or objects containing in them or having upon them any |
12 | | amounts of any substance containing lysergic acid |
13 | | diethylamide (LSD), or an analog thereof; |
14 | | (B) not less than 9 years and not more than 40 years |
15 | | with respect to: (i) 100 grams or more but less than 400 |
16 | | grams of a substance containing lysergic acid diethylamide |
17 | | (LSD), or an analog thereof, or (ii) 200 or more objects or |
18 | | 200 or more segregated parts of an object or objects but |
19 | | less than 600 objects or less than 600 segregated parts of |
20 | | an object or objects containing in them or having upon |
21 | | them any amount of any substance containing lysergic acid |
22 | | diethylamide (LSD), or an analog thereof; |
23 | | (C) not less than 12 years and not more than 50 years |
24 | | with respect to: (i) 400 grams or more but less than 900 |
25 | | grams of a substance containing lysergic acid diethylamide |
26 | | (LSD), or an analog thereof, or (ii) 600 or more objects or |
|
| | SB3640 | - 12 - | LRB103 37597 RLC 69548 b |
|
|
1 | | 600 or more segregated parts of an object or objects but |
2 | | less than 1500 objects or 1500 segregated parts of an |
3 | | object or objects containing in them or having upon them |
4 | | any amount of any substance containing lysergic acid |
5 | | diethylamide (LSD), or an analog thereof; |
6 | | (D) not less than 15 years and not more than 60 years |
7 | | with respect to: (i) 900 grams or more of any substance |
8 | | containing lysergic acid diethylamide (LSD), or an analog |
9 | | thereof, or (ii) 1500 or more objects or 1500 or more |
10 | | segregated parts of an object or objects containing in |
11 | | them or having upon them any amount of a substance |
12 | | containing lysergic acid diethylamide (LSD), or an analog |
13 | | thereof; |
14 | | (7.5)(A) not less than 6 years and not more than 30 years |
15 | | with respect to: (i) 15 grams or more but less than 100 |
16 | | grams of a substance listed in paragraph (1), (2), (2.1), |
17 | | (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or |
18 | | (26) of subsection (d) of Section 204, or an analog or |
19 | | derivative thereof, or (ii) 15 or more pills, tablets, |
20 | | caplets, capsules, or objects but less than 200 pills, |
21 | | tablets, caplets, capsules, or objects containing in them |
22 | | or having upon them any amounts of any substance listed in |
23 | | paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), |
24 | | (20.1), (21), (25), or (26) of subsection (d) of Section |
25 | | 204, or an analog or derivative thereof; |
26 | | (B) not less than 9 years and not more than 40 years |
|
| | SB3640 | - 13 - | LRB103 37597 RLC 69548 b |
|
|
1 | | with respect to: (i) 100 grams or more but less than 400 |
2 | | grams of a substance listed in paragraph (1), (2), (2.1), |
3 | | (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or |
4 | | (26) of subsection (d) of Section 204, or an analog or |
5 | | derivative thereof, or (ii) 200 or more pills, tablets, |
6 | | caplets, capsules, or objects but less than 600 pills, |
7 | | tablets, caplets, capsules, or objects containing in them |
8 | | or having upon them any amount of any substance listed in |
9 | | paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), |
10 | | (20.1), (21), (25), or (26) of subsection (d) of Section |
11 | | 204, or an analog or derivative thereof; |
12 | | (C) not less than 12 years and not more than 50 years |
13 | | with respect to: (i) 400 grams or more but less than 900 |
14 | | grams of a substance listed in paragraph (1), (2), (2.1), |
15 | | (2.2), (3), (14.1), (19), (20), (20.1), (21), (25), or |
16 | | (26) of subsection (d) of Section 204, or an analog or |
17 | | derivative thereof, or (ii) 600 or more pills, tablets, |
18 | | caplets, capsules, or objects but less than 1,500 pills, |
19 | | tablets, caplets, capsules, or objects containing in them |
20 | | or having upon them any amount of any substance listed in |
21 | | paragraph (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), |
22 | | (20.1), (21), (25), or (26) of subsection (d) of Section |
23 | | 204, or an analog or derivative thereof; |
24 | | (D) not less than 15 years and not more than 60 years |
25 | | with respect to: (i) 900 grams or more of any substance |
26 | | listed in paragraph (1), (2), (2.1), (2.2), (3), (14.1), |
|
| | SB3640 | - 14 - | LRB103 37597 RLC 69548 b |
|
|
1 | | (19), (20), (20.1), (21), (25), or (26) of subsection (d) |
2 | | of Section 204, or an analog or derivative thereof, or |
3 | | (ii) 1,500 or more pills, tablets, caplets, capsules, or |
4 | | objects containing in them or having upon them any amount |
5 | | of a substance listed in paragraph (1), (2), (2.1), (2.2), |
6 | | (3), (14.1), (19), (20), (20.1), (21), (25), or (26) of |
7 | | subsection (d) of Section 204, or an analog or derivative |
8 | | thereof; |
9 | | (8) 30 grams or more of any substance containing |
10 | | pentazocine or any of the salts, isomers and salts of |
11 | | isomers of pentazocine, or an analog thereof; |
12 | | (9) 30 grams or more of any substance containing |
13 | | methaqualone or any of the salts, isomers and salts of |
14 | | isomers of methaqualone, or an analog thereof; |
15 | | (10) 30 grams or more of any substance containing |
16 | | phencyclidine or any of the salts, isomers and salts of |
17 | | isomers of phencyclidine (PCP), or an analog thereof; |
18 | | (10.5) 30 grams or more of any substance containing |
19 | | ketamine or any of the salts, isomers and salts of isomers |
20 | | of ketamine, or an analog thereof; |
21 | | (10.6) 100 grams or more of any substance containing |
22 | | hydrocodone, or any of the salts, isomers and salts of |
23 | | isomers of hydrocodone, or an analog thereof; |
24 | | (10.7) (blank); |
25 | | (10.8) 100 grams or more of any substance containing |
26 | | dihydrocodeine, or any of the salts, isomers and salts of |
|
| | SB3640 | - 15 - | LRB103 37597 RLC 69548 b |
|
|
1 | | isomers of dihydrocodeine, or an analog thereof; |
2 | | (10.9) 100 grams or more of any substance containing |
3 | | oxycodone, or any of the salts, isomers and salts of |
4 | | isomers of oxycodone, or an analog thereof; |
5 | | (11) 200 grams or more of any substance containing any |
6 | | other controlled substance classified in Schedules I or |
7 | | II, or an analog thereof, which is not otherwise included |
8 | | in this subsection. |
9 | | (b) Any person sentenced with respect to violations of |
10 | | paragraph (1), (2), (3), (7), or (7.5) of subsection (a) |
11 | | involving 100 grams or more of the controlled substance named |
12 | | therein, may in addition to the penalties provided therein, be |
13 | | fined an amount not more than $500,000 or the full street value |
14 | | of the controlled or counterfeit substance or controlled |
15 | | substance analog, whichever is greater. The term "street |
16 | | value" shall have the meaning ascribed in Section 110-5 of the |
17 | | Code of Criminal Procedure of 1963. Any person sentenced with |
18 | | respect to any other provision of subsection (a), may in |
19 | | addition to the penalties provided therein, be fined an amount |
20 | | not to exceed $500,000. |
21 | | (b-1) Excluding violations of this Act when the controlled |
22 | | substance is fentanyl, any person sentenced to a term of |
23 | | imprisonment with respect to violations of Section 401, 401.1, |
24 | | 405, 405.1, 405.2, or 407, when the substance containing the |
25 | | controlled substance contains any amount of fentanyl, 3 years |
26 | | shall be added to the term of imprisonment imposed by the |
|
| | SB3640 | - 16 - | LRB103 37597 RLC 69548 b |
|
|
1 | | court, and the maximum sentence for the offense shall be |
2 | | increased by 3 years. |
3 | | (c) Any person who violates this Section with regard to |
4 | | the following amounts of controlled or counterfeit substances |
5 | | or controlled substance analogs, notwithstanding any of the |
6 | | provisions of subsections (a), (b), (d), (e), (f), (g) or (h) |
7 | | to the contrary, is guilty of a Class 1 felony. The fine for |
8 | | violation of this subsection (c) shall not be more than |
9 | | $250,000: |
10 | | (1) 1 gram or more but less than 15 grams of any |
11 | | substance containing heroin, or an analog thereof; |
12 | | (1.5) 1 gram or more but less than 15 grams of any |
13 | | substance containing fentanyl, or an analog thereof; |
14 | | (2) 1 gram or more but less than 15 grams of any |
15 | | substance containing cocaine, or an analog thereof; |
16 | | (2.5) 1 gram or more but less than 15 grams of any |
17 | | substance containing xylazine, or an analog thereof; |
18 | | (3) 10 grams or more but less than 15 grams of any |
19 | | substance containing morphine, or an analog thereof; |
20 | | (4) 50 grams or more but less than 200 grams of any |
21 | | substance containing peyote, or an analog thereof; |
22 | | (5) 50 grams or more but less than 200 grams of any |
23 | | substance containing a derivative of barbituric acid or |
24 | | any of the salts of a derivative of barbituric acid, or an |
25 | | analog thereof; |
26 | | (6) 50 grams or more but less than 200 grams of any |
|
| | SB3640 | - 17 - | LRB103 37597 RLC 69548 b |
|
|
1 | | substance containing amphetamine or any salt of an optical |
2 | | isomer of amphetamine, or an analog thereof; |
3 | | (6.5) (blank); |
4 | | (7)(i) 5 grams or more but less than 15 grams of any |
5 | | substance containing lysergic acid diethylamide (LSD), or |
6 | | an analog thereof, or (ii) more than 10 objects or more |
7 | | than 10 segregated parts of an object or objects but less |
8 | | than 15 objects or less than 15 segregated parts of an |
9 | | object containing in them or having upon them any amount |
10 | | of any substance containing lysergic acid diethylamide |
11 | | (LSD), or an analog thereof; |
12 | | (7.5)(i) 5 grams or more but less than 15 grams of any |
13 | | substance listed in paragraph (1), (2), (2.1), (2.2), (3), |
14 | | (14.1), (19), (20), (20.1), (21), (25), or (26) of |
15 | | subsection (d) of Section 204, or an analog or derivative |
16 | | thereof, or (ii) more than 10 pills, tablets, caplets, |
17 | | capsules, or objects but less than 15 pills, tablets, |
18 | | caplets, capsules, or objects containing in them or having |
19 | | upon them any amount of any substance listed in paragraph |
20 | | (1), (2), (2.1), (2.2), (3), (14.1), (19), (20), (20.1), |
21 | | (21), (25), or (26) of subsection (d) of Section 204, or an |
22 | | analog or derivative thereof; |
23 | | (8) 10 grams or more but less than 30 grams of any |
24 | | substance containing pentazocine or any of the salts, |
25 | | isomers and salts of isomers of pentazocine, or an analog |
26 | | thereof; |
|
| | SB3640 | - 18 - | LRB103 37597 RLC 69548 b |
|
|
1 | | (9) 10 grams or more but less than 30 grams of any |
2 | | substance containing methaqualone or any of the salts, |
3 | | isomers and salts of isomers of methaqualone, or an analog |
4 | | thereof; |
5 | | (10) 10 grams or more but less than 30 grams of any |
6 | | substance containing phencyclidine or any of the salts, |
7 | | isomers and salts of isomers of phencyclidine (PCP), or an |
8 | | analog thereof; |
9 | | (10.5) 10 grams or more but less than 30 grams of any |
10 | | substance containing ketamine or any of the salts, isomers |
11 | | and salts of isomers of ketamine, or an analog thereof; |
12 | | (10.6) 50 grams or more but less than 100 grams of any |
13 | | substance containing hydrocodone, or any of the salts, |
14 | | isomers and salts of isomers of hydrocodone, or an analog |
15 | | thereof; |
16 | | (10.7) (blank); |
17 | | (10.8) 50 grams or more but less than 100 grams of any |
18 | | substance containing dihydrocodeine, or any of the salts, |
19 | | isomers and salts of isomers of dihydrocodeine, or an |
20 | | analog thereof; |
21 | | (10.9) 50 grams or more but less than 100 grams of any |
22 | | substance containing oxycodone, or any of the salts, |
23 | | isomers and salts of isomers of oxycodone, or an analog |
24 | | thereof; |
25 | | (11) 50 grams or more but less than 200 grams of any |
26 | | substance containing a substance classified in Schedules I |
|
| | SB3640 | - 19 - | LRB103 37597 RLC 69548 b |
|
|
1 | | or II, or an analog thereof, which is not otherwise |
2 | | included in this subsection. |
3 | | (c-5) (Blank). |
4 | | (d) Any person who violates this Section with regard to |
5 | | any other amount of a controlled or counterfeit substance |
6 | | containing dihydrocodeine or classified in Schedules I or II, |
7 | | or an analog thereof, which is (i) a narcotic drug, (ii) |
8 | | lysergic acid diethylamide (LSD) or an analog thereof, (iii) |
9 | | any substance containing amphetamine or fentanyl or xylazine |
10 | | or any salt or optical isomer of amphetamine or fentanyl or |
11 | | xylazine , or an analog thereof, or (iv) any substance |
12 | | containing N-Benzylpiperazine (BZP) or any salt or optical |
13 | | isomer of N-Benzylpiperazine (BZP), or an analog thereof, is |
14 | | guilty of a Class 2 felony. The fine for violation of this |
15 | | subsection (d) shall not be more than $200,000. |
16 | | (d-5) (Blank). |
17 | | (e) Any person who violates this Section with regard to |
18 | | any other amount of a controlled substance other than |
19 | | methamphetamine or counterfeit substance classified in |
20 | | Schedule I or II, or an analog thereof, which substance is not |
21 | | included under subsection (d) of this Section, is guilty of a |
22 | | Class 3 felony. The fine for violation of this subsection (e) |
23 | | shall not be more than $150,000. |
24 | | (f) Any person who violates this Section with regard to |
25 | | any other amount of a controlled or counterfeit substance |
26 | | classified in Schedule III is guilty of a Class 3 felony. The |
|
| | SB3640 | - 20 - | LRB103 37597 RLC 69548 b |
|
|
1 | | fine for violation of this subsection (f) shall not be more |
2 | | than $125,000. |
3 | | (g) Any person who violates this Section with regard to |
4 | | any other amount of a controlled or counterfeit substance |
5 | | classified in Schedule IV is guilty of a Class 3 felony. The |
6 | | fine for violation of this subsection (g) shall not be more |
7 | | than $100,000. |
8 | | (h) Any person who violates this Section with regard to |
9 | | any other amount of a controlled or counterfeit substance |
10 | | classified in Schedule V is guilty of a Class 3 felony. The |
11 | | fine for violation of this subsection (h) shall not be more |
12 | | than $75,000. |
13 | | (i) This Section does not apply to the manufacture, |
14 | | possession or distribution of a substance in conformance with |
15 | | the provisions of an approved new drug application or an |
16 | | exemption for investigational use within the meaning of |
17 | | Section 505 of the Federal Food, Drug and Cosmetic Act. |
18 | | (j) (Blank). |
19 | | (Source: P.A. 99-371, eff. 1-1-16; 99-585, eff. 1-1-17; |
20 | | 100-368, eff. 1-1-18 .) |